Bio-Techne Corp (TECH) has had a mixed financial performance. The
company declared a dividend, yet
Q4 results declined. Meanwhile, major financial groups have increased their stake in the company. Interestingly,
shares have been estimated to be significantly above their intrinsic value. Recent quarters' results have shown both hits and misses amid market challenges. The
appointment of new CEO, Kim Kelderman, is noteworthy, along with other strategic board appointments. Bio-Techne's collaborations and partnership announcements help spotlight its expansion and promotion of innovation. Notably, the
partnership with Thermo Fisher provides an opportunity to distribute Bio-Techne's products across Europe. Recent
acquisition of Lunaphore is expected to boost cancer diagnostics through spatial biology. The
surpassing of peer-reviewed publications citing RNAscope technology and the
receipt of various awards offer further recognition of Bio-Techne's innovative contributions to the field. However, the
EPS miss and insider share selling suggest potential concerns. Regardless, Overall, Bio-Techne remains a player in the biotech market, with various analysts suggesting a 'Moderate Buy' on its stocks.
Bio-Techne Corp TECH News Analytics from Thu, 04 Aug 2022 07:00:00 GMT to Sun, 19 May 2024 14:53:59 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 4
